Document is current
Any future updates will be listed below
-
Authors
Testa, Stefano
Pal, Aastha
Subramanian, Ajay
Varma, Sushama
Tang, Jack Pengfei
Graham, Danielle
Arfan, Sara
Pan, Minggui
Bui, Nam Q.
Ganjoo, Kristen N.
Dry, Sarah
Huang, Paul
van de Rijn, Matt
Jiang, Wei
Kalbasi, Anusha
Moding, Everett J.
-
Funding
Funding for this research was provided by:
Tad and Diane Taube Family Foundation
National Institutes of Health (K08CA245181)
Highlight Therapeutics
Cancer Research Institute (CRI14104)
My Blue Dots organization
- License Information
-
More Information
Article History
Received: 25 January 2025
Accepted: 14 July 2025
First Online: 14 August 2025
Declarations
:
: All samples analyzed in this study were collected with informed consent from subjects enrolled on protocols approved by the Institutional Review Boards at Stanford University (#11977) and University of California Los Angeles (#19-000419). All patients gave written informed consent to participate in the study prior to sample collection. All studies on human samples were conducted conforming to the principles of the Helsinki Declaration.
: Patients provided written informed consent for publication of the information reported in Supplementary Table 1.
: E.J.M. has served as a consultant for GLG and Guidepoint. A.K. serves on the advisory board and holds stock for Dispatch Biotherapeutics, and Certis Oncology and consults for Sastra Cell Therapy. W.J. serves as CSO for JWE Science Technology, Inc., Bejing, China, which owns the intellectual property of the IMMUNE technology. The remaining authors declare that they do not have any competing interests.
